EGFR and breast cancer: Lee et al. [45, 46] revealed the ability of FAM83A to confer resistance to epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) through interactions with c-RAF and PI3K p85 in BC.